

Respiratorius Q1 2023 - The partner hunt continues

Redeye leaves its comments on Respiratorius following its Q1 2023 report, which did not contain any significant surprises. As a result of raised WACC and some financial fine-tuning we lower our fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Respiratorius Q1 2023 - The partner hunt continues](#)